MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

NCT03767335 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Breast Cancer

Interventions

DRUG: MEN1611
DRUG: Trastuzumab
DRUG: Fulvestrant

Sponsor

Menarini Group